Updated Financial Calendar 2016
(Oslo, Norway, 11 March 2016) Bionor Pharma ASA (OSE:BIONOR) has changed the date for the publication of the Annual Report 2015 and now scheduled its financial calendar for the remainder of 2016 as follows:
31 March 2016 - Annual Report 2015
21 April 2016 - Annual General Meeting
11 May 2016 - Q1 2016 Interim Financial Report
23 August 2016 - Q2 2016 Interim Financial Report
16 November 2016 - Q3 2016 Interim Financial Report
The dates may be subject to change.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, email@example.com
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by significantly reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.